What is TrialNet?
TrialNet operates as a collaborative network of leading academic institutions, healthcare professionals, and scientists dedicated to advancing type 1 diabetes (T1D) research. The organization offers complimentary risk screening for individuals with a family history of T1D and spearheads innovative clinical studies designed to slow or prevent the onset of the disease. By identifying T1D in its nascent stages and fostering global research collaborations, TrialNet aims to accelerate the development of effective treatment options and ultimately realize a future free from T1D. With over 100 screening and study locations worldwide, TrialNet actively engages communities and raises awareness about the condition.
How much funding has TrialNet raised?
TrialNet has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for TrialNet?
The substantial capital infusion, contextualized by a large-scale late-stage funding environment and a major strategic investment, positions TrialNet for significant expansion and operational scaling. This backing is expected to fuel further advancements in their clinical studies and broaden the reach of their risk screening programs. The company's focus on early detection and prevention, coupled with its extensive network of research partners, suggests a strategic trajectory aimed at solidifying its role as a pivotal player in global T1D research and therapeutic development.
See full TrialNet company page
